



## Tumor Microenvironment of Breast Cancer

Guest Editor:

**Dr. Masanori Oshi**

1. Department of Surgical  
Oncology, Roswell Park  
Comprehensive Cancer Center,  
Buffalo, NY 14263, USA

2. Department of  
Gastroenterological Surgery,  
Graduate School of Medicine,  
Yokohama City University,  
Yokohama 236-0004, Japan

Deadline for manuscript  
submissions:

**closed (15 March 2025)**

### Message from the Guest Editor

Dear Colleagues,

The tumor microenvironment (TME) consists of not only cancer cells, but many other types of cells, including stromal and immune cells that play critical roles in cancer biology. The interactions that occur within the TME include fundamental mechanisms that affect tumor progression and treatment outcomes. Recently developed cancer therapeutics are targeting these interactions within the TME, including immune- and stroma-targeted approaches. The tumor immune microenvironment significantly influences patient survival, and neoadjuvant therapy with immune checkpoint inhibitors is now considered the standard of care for some triple negative breast cancers. Despite these recent advancements, many breast cancer patients still encounter resistance to treatment, progression of disease, and poor outcomes. In this Special Issue of *Cancers*, we hope to gather the latest findings (original articles), as well as summary reports (review articles) that discuss the breast cancer TME that will help the next generation of researchers.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI